Overview

Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer

Status:
Terminated

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the pathological complete response (pCR) rate in triple-negative or Her2 positive breast cancer patients treated with neoadjuvant docetaxel, anthracycline and cyclophosphamide (TAC) or docetaxel and cyclophosphamide (TC) regimen.

Phase:

Phase 3

Details

Lead Sponsor:

Shanghai Jiao Tong University School of Medicine

Treatments:

Cyclophosphamide
Docetaxel
Doxorubicin
Epirubicin
Liposomal doxorubicin